Prelude Therapeutics Inc
NASDAQ:PRLD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Prelude Therapeutics Inc
NASDAQ:PRLD
|
US |
|
T
|
Thorne Healthtech Inc
F:F7G
|
US |
|
Global-E Online Ltd
NASDAQ:GLBE
|
IL |
|
Robot Home Inc
TSE:1435
|
JP |
|
Humacyte Inc
NASDAQ:HUMA
|
US |
|
Americold Realty Trust
NYSE:COLD
|
US |
|
P
|
Polymac Thermoformers Ltd
BSE:537573
|
IN |
|
M
|
MoneyGram International Inc
F:9M1N
|
US |
|
COSCO SHIPPING Development Co Ltd
SSE:601866
|
CN |
|
D
|
DPC Dash Ltd
HKEX:1405
|
CN |
|
Z
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
|
CN |
Prelude Therapeutics Inc
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 116 full-time employees. The company went IPO on 2020-09-25. The firm is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The firm is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 116 full-time employees. The company went IPO on 2020-09-25. The firm is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The firm is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
